WHEN a 44-year-old man began experiencing a common symptom experienced by millions, he decided to get checked out by medical ...

"CereVasc scores safety and efficacy win in hydrocephalus treatment pilot study" was originally created and published by Medical Device Network, a GlobalData owned brand.

The hydrocephalus shunt market is experiencing rapid innovation, with newer, more efficient shunt systems being introduced to the market. These advancements are improving patient outcomes and catering ...

CereVasc, Inc. announced the initial results of its United States pilot clinical study of the CereVasc eShunt system in the ...

Background Hydrocephalus is a significant contributor to morbidity following aneurysmal subarachnoid hemorrhage (aSAH). We aimed to investigate the association between primary treatment modality and ...

Valentina had been in Philadelphia since August 2024, receiving treatment for myelomeningocele ... crashed just 30 seconds after takeoff from Northeast Philadelphia Airport. Valentina had battled ...

The classic triad of symptoms gait disturbance, cognitive dysfunction, and urinary incontinence generally responds to treatment if present for less than 2 years' duration. Gait and balance ...